Exited position

George Soros’s Neurocrine Biosciences Inc (NBIX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Soros Fund ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2007Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares239.82KHighest verified quarter-end share count
Quarters reported20Verified quarters with shares above zero
What happened?

Soros Fund Management first reported Neurocrine Biosciences Inc in Q2 2007. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Soros Fund Management sold the entire position in Q2 2025, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2025
Sold the entire position−239.82K shares · No shares reported at quarter-end
Q1 2025
Bought 19.9% more+39.82K shares · 239.82K shares reported after the change
Filing context

Quarter-end price $110.60 · Estimated holding basis $126.96

Q4 2024
Bought 33.3% more+50.00K shares · 200.00K shares reported after the change
Filing context

Quarter-end price $136.50 · Estimated holding basis $130.22

Q3 2024
Sold 23.0% of the position−44.78K shares · 150.00K shares remained
Filing context

Quarter-end price $115.22 · Estimated holding basis $128.12

Q2 2024
Bought 21.9% more+35.00K shares · 194.78K shares reported after the change
Filing context

Quarter-end price $137.67 · Estimated holding basis $128.12

Q1 2024
Sold 13.6% of the position−25.22K shares · 159.78K shares remained
Filing context

Quarter-end price $137.92 · Estimated holding basis $126.03

Portfolio importance

How important was Neurocrine Biosciences Inc in Soros Fund Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.5%Q1 2025
Last reported rank#55of 189 reported positions
Peak portfolio weight0.6%Q2 2024
Best historical rank#43Q2 2024
At peak importanceQ2 2024
NBIX
0.6%
Largest holding
5.5%
Cross-investor discovery

Who else owns Neurocrine Biosciences Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Joel GreenblattGotham Asset Management
NBIX0.1% of reported portfolio
Ray DalioBridgewater Associates, LP
NBIX0.1% of reported portfolio
Explore Neurocrine Biosciences Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$157.222026-09-14

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Soros Fund Management LLC’s Form 13F disclosures—not George Soros’s personal brokerage account. George Soros founded the firm; its current CEO and chief investment officer is Dawn Fitzpatrick. Form 13F does not reveal exact trade dates, execution prices or the purpose of an option position.